A 2012 German study into metabolic syndrome found that testosterone-replacement therapy improved the symptoms of metabolic syndrome in men suffering from low testosterone levels. Their findings were presented at the 94th General meeting of the Endocrine Society in 2012 (reference: https://www.endocrine.org/~/media/endosociety/Files/News%20Room/ENDO/RSB%20Pdf.pdf See page XIV entry for SUN-0097)
Metabolic syndrome is made up of a cluster of medical issues that can increase the risk of heart and blood-vessel disease as well as type 2 diabetes. The issues normally include excess body weight, especially around the waist and torso, and abnormally high levels of fat in the blood, known as lipids. In particular, patients with metabolic syndrome have high blood levels of “bad fats” (triglycerides and low-density lipoproteins). They also have issues with low levels of “healthy fats” (high-density lipoproteins). They also often have high blood pressure and high sugar levels in their blood.
Research has, for many years, shown a link between metabolic syndrome to low blood testosterone levels.
“When indicated, testosterone treatment is both essential and safe in elderly patients with symptomatic late onset hypogonadism [authors note: shows symptoms, mature aged with low testosterone], or testosterone deficiency,” said the study leader Dr. Aksam A. Yassin, chairman of the Institute of Urology & Andrology in Norderstedt-Hamburg, Germany (http://qimic.hamad.qa/en/speakers/d_r_aksam_yassin/d_r_aksam_yassin.aspx).
Researchers found that the incidence of metabolic syndrome dropped from 56 to 30 percent after 57 months of treatment [authors note: treatment had beneficitial affects within a few months; long before the end of the study. The study continued for the length of time it did because that is how the study was planned and to check for any futher effects – good or ill – there were none] with testosterone-replacement therapy. In addition, triglycerides, and levels of blood sugar and pressure were reduced significantly, while the average waist circumference shrank by 11 centimeters.
Beginning in 2004, the researchers collected information from 261 mature patients who were suffering from low testosterone levels (hypogonadism) and sexual dysfunction. Patients received 1,000 milligrams of undeconate a long-acting testosterone drug on the first day of the study, again six week later, and then every three months. At each visit, patients underwent testing of hormone levels, blood-sugar and lipid concentrations, and blood pressure. The research continued for a further four years and 3 months.
“We hypothesized that long-term testosterone improves metabolic syndrome, and found that this intervention improved all three components of obesity, including waist circumference, weight, and body-mass index; diabetes control; poor lipids profile; and blood pressure,” Yassin said.
To determine the presence of metabolic syndrome among study participants, investigators used the definition from the International Diabetes Federation. Participants were diagnosed with the syndrome if they displayed central-body obesity combined with two other risk factors. These included elevated triglycerides levels, decreased high-density lipoproteins, high blood pressure, and excessive blood-sugar concentrations.
Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome (http://onlinelibrary.wiley.com/doi/10.1111/j.1743-6109.2010.01931.x/abstract)
Hypogonadism and Metabolic Syndrome: Implications for Testosterone Therapy (http://www.sciencedirect.com/science/article/pii/S0022534701684234)
Let's talk about wellness and anti-aging. Join our community today! http://t.co/F4rPIUHkwE
— Anti Aging Today (@StopAgingUS) January 5, 2015